pipette
ENEnglish

HCV incidence and prevalence trends among people who use drugs in France 2004 to 2023

Chiara Elisa Sabbatini, Yann Le Strat, Christophe Bonaldi, Cécile Brouard, Martin Audran, Leïla Saboni, Jean‐Baptiste Richard, Amélie David, Catherine Gaudy‐Graffin, Stéphane Chevaliez, Francis Barin, Karl Stéfic, Marie Jauffret‐Roustide

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Abstract Hepatitis C virus (HCV) remains a key public health challenge, particularly among people who use and inject drugs (PWUD, PWID). While direct-acting antivirals (DAA) have revolutionized HCV treatment, meeting the WHO’s 2030 elimination target requires accurate estimation of incidence and prevalence to guide prevention and care. We analyze cross-sectional surveys conducted in France in 2004, 2013, and 2023, recruiting PWUD at harm reduction services and collecting behavioral and biological data. We estimate age-and time-dependent prevalence of HCV antibodies and HCV RNA using multivariate regression models while incidence was estimated from two-state transmission models. The demographic profile of PWUD has aged over time (mean age 35 years in 2004 vs. 44 in 2023) while injection prevalence remained stable (61.7% in 2023). Between 2013 and 2023, HCV burden declined substantially: HCV RNA prevalence fell from 19.4% (95% CI 16.3–23.0) to 9.5% (7.2–12.3) among all PWUD, and from 29.6% to 14.5% among PWID. Incidence among PWID decreased from 6.5 (4.1–8.0) to 2.4 (1.4–4.2) per 100 person-years. These reductions likely reflect the combined impact of DAA scale-up and harm reduction policies, marking substantial progress toward elimination targets. However, ongoing transmission highlights persistent barriers requiring targeted public health actions.

Resultado principalEl resumen no menciona limitaciones.

Apareció: martes, 13 de octubre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-78598-3